Prot #ALXN2220-ATTRCM-301: DepleTTR-CM: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Project: Research project

Project Details

StatusActive
Effective start/end date10/1/24 → 10/1/27

Funding

  • Quintiles, Inc. (Prot #ALXN2220-ATTRCM-301 AMD 1 // Prot #ALXN2220-ATTRCM-301 ...)
  • Alexion Pharmaceuticals, Inc (Prot #ALXN2220-ATTRCM-301 AMD 1 // Prot #ALXN2220-ATTRCM-301 ...)